A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 14, Issue 3, Pages 485-493
Publisher
Informa Healthcare
Online
2015-02-07
DOI
10.1517/14740338.2015.1007040
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
- (2014) J. Tabernero et al. CLINICAL CANCER RESEARCH
- Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review
- (2014) Eugen F Mesaros et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Successful Crizotinib Rechallenge After Crizotinib-induced Interstitial Lung Disease
- (2014) M. Tachihara et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- A Severe Photosensitivity Dermatitis Caused by Crizotinib
- (2014) Matthew G. Oser et al. Journal of Thoracic Oncology
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib Reduces the Rate of Dark Adaptation in the Rat Retina Independent of ALK Inhibition
- (2014) Chang-Ning Liu et al. TOXICOLOGICAL SCIENCES
- Crizotinib: A New Treatment Option for ALK-Positive Non-Small Cell Lung Cancer
- (2013) Cindy L O'Bryant et al. ANNALS OF PHARMACOTHERAPY
- Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
- (2013) Thomas H. Marsilje et al. JOURNAL OF MEDICINAL CHEMISTRY
- Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease
- (2013) Satoru Yanagisawa et al. Journal of Thoracic Oncology
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes
- (2013) Kimberly R. Doherty et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
- (2012) Andrew J. Weickhardt et al. CANCER
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Crizotinib for the Treatment of ALK -Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
- (2012) Sai-Hong Ignatius Ou et al. ONCOLOGIST
- Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma
- (2012) Andres Morales La Madrid et al. Targeted Oncology
- Targeting Anaplastic Lymphoma Kinase in Lung Cancer
- (2011) A. T. Shaw et al. CLINICAL CANCER RESEARCH
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- (2011) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Inhibitory effect of hepatocyte growth factor on cardiomyocytes apoptosis is partly related to reduced calcium sensing receptor expression during a model of simulated ischemia/reperfusion
- (2010) Ling Yan et al. MOLECULAR BIOLOGY REPORTS
- Anaplastic lymphoma kinase: signalling in development and disease
- (2009) Ruth H. Palmer et al. BIOCHEMICAL JOURNAL
- A mouse model for EML4-ALK-positive lung cancer
- (2008) M. Soda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started